Related references
Note: Only part of the references are listed.Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa
Bartolome Moya et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa
Maria A. Gomis-Font et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update
Ester del Barrio-Tofino et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
The Novel β-Lactam Enhancer Zidebactam Augments the In Vivo Pharmacodynamic Activity of Cefepime in a Neutropenic Mouse Lung Acinetobacter baumannii Infection Model
S. S. Bhagwat et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model
Marguerite L. Monogue et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections
Juan P. Horcajada et al.
CLINICAL MICROBIOLOGY REVIEWS (2019)
In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model
Safa S. Almarzoky Abuhussain et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa
Pablo A. Fraile-Ribot et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
The Versatile Mutational Resistome of Pseudomonas aeruginosa
Carla Lopez-Causape et al.
FRONTIERS IN MICROBIOLOGY (2018)
Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model
Lindsay M. Avery et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Mutation-Driven Evolution of Pseudomonas aeruginosa in the Presence of either Ceftazidime or Ceftazidime-Avibactam
Fernando Sanz-Garcia et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the Caenorhabditis elegans Pseudomonas aeruginosa Infection Model
Irina Sanchez-Diener et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation
Shawn H. MacVane et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vivo Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa
Pablo A. Fraile-Ribot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates
Gabriel Cabot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Amdinocillin (Mecillinam) Resistance Mutations in Clinical Isolates and Laboratory-Selected Mutants of Escherichia coli
Elisabeth Thulin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins
M. Berrazeg et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC
Sushmita D. Lahiri et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC
Gabriel Cabot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Fast gapped-read alignment with Bowtie 2
Ben Langmead et al.
NATURE METHODS (2012)
Overexpression of AmpC and Efflux Pumps in Pseudomonas aeruginosa Isolates from Bloodstream Infections: Prevalence and Impact on Resistance in a Spanish Multicenter Study
Gabriel Cabot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
A framework for variation discovery and genotyping using next-generation DNA sequencing data
Mark A. DePristo et al.
NATURE GENETICS (2011)
Differential Selection of Single-Step AmpC or Efflux Mutants of Pseudomonas aeruginosa by Using Cefepime, Ceftazidime, or Ceftobiprole
Anne Marie Queenan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance
A. Oliver et al.
CLINICAL MICROBIOLOGY AND INFECTION (2010)
The Sequence Alignment/Map format and SAMtools
Heng Li et al.
BIOINFORMATICS (2009)
Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms
Philip D. Lister et al.
CLINICAL MICROBIOLOGY REVIEWS (2009)
Pseudomonas aeruginosa: a formidable and ever-present adversary
K. G. Kerr et al.
JOURNAL OF HOSPITAL INFECTION (2009)
Genetic Adaptation of Pseudomonas aeruginosa to the Airways of Cystic Fibrosis Patients Is Catalyzed by Hypermutation
A. Mena et al.
JOURNAL OF BACTERIOLOGY (2008)
Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa
D Hocquet et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection
A Oliver et al.
SCIENCE (2000)
Share Paper
